{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for crizotinib in Related Substance Name (approximate match)
Showing 1 - 10 of 10 results
Status:
US Approved Rx
(2011)
Source:
NDA202570
(2011)
Source URL:
First approved in 2011
Source:
NDA202570
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
(S)-crizotinib was discovered as an attractive chemical entity for further pre-clinical evaluation, and small-molecule inhibitors of MTH1 as a promising novel class of anticancer agents.
Status:
Possibly Marketed Outside US
Source:
Octaplasma by Octapharma Pharmazeutika Produktionsges M B H [Canada]
Source URL:
First approved in 2013
Source:
BLA125416
Source URL:
Class:
MIXTURE
Status:
US Approved Rx
(2011)
Source:
NDA202570
(2011)
Source URL:
First approved in 2011
Source:
NDA202570
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
(S)-crizotinib was discovered as an attractive chemical entity for further pre-clinical evaluation, and small-molecule inhibitors of MTH1 as a promising novel class of anticancer agents.
Status:
US Approved Rx
(2011)
Source:
NDA202570
(2011)
Source URL:
First approved in 2011
Source:
NDA202570
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
(S)-crizotinib was discovered as an attractive chemical entity for further pre-clinical evaluation, and small-molecule inhibitors of MTH1 as a promising novel class of anticancer agents.
